Kamada (KMDA) to Release Earnings on Wednesday

Kamada (NASDAQ:KMDA) will issue its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of $0.07 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $42.47 million for the quarter, compared to the consensus estimate of $39.70 million. Kamada had a return on equity of 6.15% and a net margin of 9.75%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Stock Up 1.7 %

Shares of KMDA opened at $6.10 on Tuesday. The business has a fifty day moving average of $5.44 and a 200 day moving average of $5.45. The company has a market cap of $350.63 million, a PE ratio of 22.59 and a beta of 1.05. Kamada has a 52-week low of $4.58 and a 52-week high of $6.53.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on KMDA. StockNews.com downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Thursday, August 15th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.